The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study

Anxiety and DepressionBipolar Disorder

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment

Int J Bipolar Disord.

Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A

doi: 10.1186/

Epilepsy

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307

Epilepsia.

Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A

doi: 10.1111/epi.14044.

Migraine and Headache

STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD^® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

Headache

Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB

doi: 10.1111/head.14184

Further Publications NeurologyFurther Publications Psychiatry

Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study

Bipolar Disord.

Earley W, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, Calabrese JR

doi: 10.1111/bdi.12852.

Aging and Cognitive FunctionsBipolar Disorder

Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study

Lancet Psychiatry.

Yatham LN, Mackala S, Basivireddy J, Ahn S, Walji N, Hu C, Lam RW, Torres IJ

doi: 10.1016/

EpilepsyPsychosis and Schizophrenia

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

Lancet Psychiatry.

Kahn RS, Winter van Rossum , Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Díaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthøj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE; OPTiMiSE study group

doi: 10.1016/

Migraine and Headache

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

BMC Neurol.

Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL

doi: 10.1186/s12883-018-1193-2.

Migraine and Headache

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

Neurology.

Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA

doi: 10.1212/

Bipolar Disorder

A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression

J Affect Disord.

Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN

doi: 10.1016/j.jad.2019.11.098.

Related content

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307

STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study

Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression

STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD^® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients